Search clinical trials for: CTP-543, 12 mg BID

Total 855 results

Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Concert Pharmaceuticals

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects

Healthy

Australia
Concert Pharmaceuticals

Completed

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

Healthy

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)

Alopecia Areata

Spain, United States, Poland, Canada, France, Germany, Hungary
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) (THRIVE-AA1)

Alopecia Areata

United States, Canada, Poland, France, Spain
Concert Pharmaceuticals

Enrolling by invitation

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Concert Pharmaceuticals

Active, not recruiting

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

Spain, Germany, Poland, France, Hungary
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Renal Impairment

United States
Concert Pharmaceuticals

Completed

Food Effect Study of CTP-543 in Healthy Volunteers

Healthy

United States
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

Hepatic Impairment

United States
Concert Pharmaceuticals

Completed

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

Health Volunteers

United States
Concert Pharmaceuticals

Completed

A Study to Evaluate the Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals
Celerion

Completed

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

Healthy Volunteers

United States
Concert Pharmaceuticals

Completed

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

Healthy Volunteers

United States
Hamamatsu University

Completed

Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication

Gastritis Associated With Helicobacter Pylori

Japan
Concert Pharmaceuticals

Completed

Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

Healthy Volunteers

United States
Daewon Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects

Healthy Males
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

Fungal Infections
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
Vifor (International) Inc.
Labcorp Drug Development Inc

Withdrawn

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Beta-Thalassemia

United States, Bulgaria, Israel
Innovation Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Chronic Stable Plaque Psoriasis

United States
AstraZeneca

Completed

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

Chronic Cough

China
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

Chronic Cough

Canada, Czechia, Denmark, Hungary, Peru, Poland, Ukraine, United Kingdom, United States, Australia, China, Colombia, Germany, Guatemala, Israel, Italy, Malaysia, New Zealand, South Africa, Turkey
Altavant Sciences GmbH
Parexel; Altavant Sciences, Inc.

Completed

Multiple-Ascending Dose in Japanese Patients Bridging Study

Healthy

United States
Altavant Sciences GmbH

Completed

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)

Pulmonary Arterial Hypertension

United States, Spain, United Kingdom, Czechia, Serbia, Canada, Poland, Italy, Bosnia and Herzegovina, Austria, Germany, Belgium, Bulgaria, France, Latvia, Moldova, Republic of, Ukraine
Kanion & Huawe Medicine Co.,Ltd

Terminated

Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

Obesity

China
Eisai Inc.

Completed

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Obesity

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF2)

Cystic Fibrosis

United States
Boston University

Completed

Safety and Effect of Doxycycline in Patients With Amyloidosis

Amyloidosis

United States
Future Medicine

Recruiting

FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

Spain, Hungary, Poland
Kaohsiung Veterans General Hospital.

Completed

Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies

Helicobacter Pylori Infection

Taiwan
Hoffmann-La Roche

Completed

Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection

Chronic Hepatitis C

United States, Puerto Rico
Kaplan Medical Center

Unknown

Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome

Infection, Bacterial | Pacemaker Complication
BioMed Valley Discoveries, Inc

Completed

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Advanced Solid Tumors

United States
BioMed Valley Discoveries, Inc

Completed

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Dr. Reddy's Laboratories Limited
XenoPort, Inc.

Completed

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Psoriasis

United States
RFS Pharma, LLC

Withdrawn

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects

Human Immunodeficiency Virus Infection
Dana-Farber Cancer Institute
BioMed Valley Discoveries, Inc

Active, not recruiting

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Uveal Melanoma

United States
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites

Hypertension | Congestive Heart Failure

Switzerland
University of Aarhus
Aarhus University Hospital

Completed

Does the Bioactive Substance in Coffee, Cafestol, Have Preventive Properties on Type-2-diabetes? (Acute Substudy)

Obesity, Abdominal

Denmark
Suzhou Kintor Pharmaceutical Inc,
Suzhou Koshine Biomedica, Inc.

Active, not recruiting

Phase III Study of KX-826 With Adult Male Patients With AGA

Androgenetic Alopecia

China
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Oral Administration

Healthy

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

Hypertension
BioMed Valley Discoveries, Inc

Completed

Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers

Healthy

3

Subscribe